Selected research
Industry Research
Neurodegenerative Disease CDMO Industry Research Report 2026
Market perspective
The global Neurodegenerative Disease CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neurodegenerative Disease CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neurodegenerative Disease CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neurodegenerative Disease CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neurodegenerative Disease CDMO include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai and Fujirebio Holdings, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neurodegenerative Disease CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neurodegenerative Disease CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neurodegenerative Disease CDMO Market by Company
AC Immune
Alterity Therapeutics
Biogen
Charles River Laboratories
Coave Therapeutics
Sysmex Corp
Donanemab
Eisai
Fujirebio Holdings
GenSight Biologics
Neuropore Therapies
Nevrargenics
PPD
Samsung Biologics
Sanofi(Vigil Neuroscience)
Neurodegenerative Disease CDMO Segment by Type
Small Molecule Drug CDMO
Biopharmaceutical CDMO
Cell and Gene Therapy (CGT) CDMO
OtherS
Neurodegenerative Disease CDMO Segment by Application
Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Amyotrophic Lateral Sclerosis (ALS)
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Others
Neurodegenerative Disease CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neurodegenerative Disease CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule Drug CDMO
- Biopharmaceutical CDMO
- Cell and Gene Therapy (CGT) CDMO
- OtherS
Applications
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Others
Companies covered
- AC Immune
- Alterity Therapeutics
- Biogen
- Charles River Laboratories
- Coave Therapeutics
- Sysmex Corp
- Donanemab
- Eisai
- Fujirebio Holdings
- GenSight Biologics
- Neuropore Therapies
- Nevrargenics
- PPD
- Samsung Biologics
- Sanofi(Vigil Neuroscience)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neurodegenerative Disease CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecule Drug CDMO
- 2.2.3 Biopharmaceutical CDMO
- 2.2.4 Cell and Gene Therapy (CGT) CDMO
- 2.2.5 OtherS
- 2.3 Neurodegenerative Disease CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Alzheimer's Disease
- 2.3.3 Parkinson's Disease
- 2.3.4 Huntington's Disease
- 2.3.5 Amyotrophic Lateral Sclerosis (ALS)
- 2.3.6 Multiple System Atrophy (MSA)
- 2.3.7 Progressive Supranuclear Palsy (PSP)
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Neurodegenerative Disease CDMO Breakdown Data by Type
- 3.1 Global Neurodegenerative Disease CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2027-2032)
4 Neurodegenerative Disease CDMO Breakdown Data by Application
- 4.1 Global Neurodegenerative Disease CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neurodegenerative Disease CDMO Market Perspective (2021-2032)
- 5.2 Global Neurodegenerative Disease CDMO Growth Trends by Region
- 5.2.1 Global Neurodegenerative Disease CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neurodegenerative Disease CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Neurodegenerative Disease CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Neurodegenerative Disease CDMO Market Dynamics
- 5.3.1 Neurodegenerative Disease CDMO Industry Trends
- 5.3.2 Neurodegenerative Disease CDMO Market Drivers
- 5.3.3 Neurodegenerative Disease CDMO Market Challenges
- 5.3.4 Neurodegenerative Disease CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neurodegenerative Disease CDMO Players by Revenue
- 6.1.1 Global Top Neurodegenerative Disease CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Neurodegenerative Disease CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Neurodegenerative Disease CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neurodegenerative Disease CDMO Head Office and Area Served
- 6.4 Global Neurodegenerative Disease CDMO Players, Product Type & Application
- 6.5 Global Neurodegenerative Disease CDMO Manufacturers Established Date
- 6.6 Global Neurodegenerative Disease CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neurodegenerative Disease CDMO Market Size (2021-2032)
- 7.2 North America Neurodegenerative Disease CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
- 7.4 North America Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neurodegenerative Disease CDMO Market Size (2021-2032)
- 8.2 Europe Neurodegenerative Disease CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
- 8.4 Europe Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neurodegenerative Disease CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Neurodegenerative Disease CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neurodegenerative Disease CDMO Market Size (2021-2032)
- 10.2 South America Neurodegenerative Disease CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
- 10.4 South America Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neurodegenerative Disease CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Neurodegenerative Disease CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neurodegenerative Disease CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AC Immune
- 12.1.1 AC Immune Company Information
- 12.1.2 AC Immune Business Overview
- 12.1.3 AC Immune Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.1.4 AC Immune Neurodegenerative Disease CDMO Product Portfolio
- 12.1.5 AC Immune Recent Developments
- 12.2 Alterity Therapeutics
- 12.2.1 Alterity Therapeutics Company Information
- 12.2.2 Alterity Therapeutics Business Overview
- 12.2.3 Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.2.4 Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio
- 12.2.5 Alterity Therapeutics Recent Developments
- 12.3 Biogen
- 12.3.1 Biogen Company Information
- 12.3.2 Biogen Business Overview
- 12.3.3 Biogen Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.3.4 Biogen Neurodegenerative Disease CDMO Product Portfolio
- 12.3.5 Biogen Recent Developments
- 12.4 Charles River Laboratories
- 12.4.1 Charles River Laboratories Company Information
- 12.4.2 Charles River Laboratories Business Overview
- 12.4.3 Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.4.4 Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio
- 12.4.5 Charles River Laboratories Recent Developments
- 12.5 Coave Therapeutics
- 12.5.1 Coave Therapeutics Company Information
- 12.5.2 Coave Therapeutics Business Overview
- 12.5.3 Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.5.4 Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio
- 12.5.5 Coave Therapeutics Recent Developments
- 12.6 Sysmex Corp
- 12.6.1 Sysmex Corp Company Information
- 12.6.2 Sysmex Corp Business Overview
- 12.6.3 Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.6.4 Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio
- 12.6.5 Sysmex Corp Recent Developments
- 12.7 Donanemab
- 12.7.1 Donanemab Company Information
- 12.7.2 Donanemab Business Overview
- 12.7.3 Donanemab Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.7.4 Donanemab Neurodegenerative Disease CDMO Product Portfolio
- 12.7.5 Donanemab Recent Developments
- 12.8 Eisai
- 12.8.1 Eisai Company Information
- 12.8.2 Eisai Business Overview
- 12.8.3 Eisai Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.8.4 Eisai Neurodegenerative Disease CDMO Product Portfolio
- 12.8.5 Eisai Recent Developments
- 12.9 Fujirebio Holdings
- 12.9.1 Fujirebio Holdings Company Information
- 12.9.2 Fujirebio Holdings Business Overview
- 12.9.3 Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.9.4 Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio
- 12.9.5 Fujirebio Holdings Recent Developments
- 12.10 GenSight Biologics
- 12.10.1 GenSight Biologics Company Information
- 12.10.2 GenSight Biologics Business Overview
- 12.10.3 GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.10.4 GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio
- 12.10.5 GenSight Biologics Recent Developments
- 12.11 Neuropore Therapies
- 12.11.1 Neuropore Therapies Company Information
- 12.11.2 Neuropore Therapies Business Overview
- 12.11.3 Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.11.4 Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio
- 12.11.5 Neuropore Therapies Recent Developments
- 12.12 Nevrargenics
- 12.12.1 Nevrargenics Company Information
- 12.12.2 Nevrargenics Business Overview
- 12.12.3 Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.12.4 Nevrargenics Neurodegenerative Disease CDMO Product Portfolio
- 12.12.5 Nevrargenics Recent Developments
- 12.13 PPD
- 12.13.1 PPD Company Information
- 12.13.2 PPD Business Overview
- 12.13.3 PPD Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.13.4 PPD Neurodegenerative Disease CDMO Product Portfolio
- 12.13.5 PPD Recent Developments
- 12.14 Samsung Biologics
- 12.14.1 Samsung Biologics Company Information
- 12.14.2 Samsung Biologics Business Overview
- 12.14.3 Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.14.4 Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio
- 12.14.5 Samsung Biologics Recent Developments
- 12.15 Sanofi(Vigil Neuroscience)
- 12.15.1 Sanofi(Vigil Neuroscience) Company Information
- 12.15.2 Sanofi(Vigil Neuroscience) Business Overview
- 12.15.3 Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2021-2026)
- 12.15.4 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio
- 12.15.5 Sanofi(Vigil Neuroscience) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst